Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
Clinical Cancer Research2009Vol. 15(6), pp. 2166–2173
Citations Over TimeTop 10% of 2009 papers
Theo Nicholaou, Lisa M. Ebert, Ian D. Davis, Grant A. McArthur, Heather Jackson, Nektaria Dimopoulos, Bee Shin Tan, Eugene Maraskovsky, Lena Miloradovic, Wendie Hopkins, Linda Pan, Ralph Venhaus, Eric W. Hoffman, Weisan Chen, Jonathan Cebon
Abstract
Our results point to a tumor-induced systemic immune suppression, showing a clear association between the stage of melanoma progression, the number of Treg in the blood, and the clinical and immunologic efficacy of the NY-ESO-1 ISCOMATRIX cancer vaccine.
Related Papers
- The acquisition and loss of antigen-specific cellular immune responsiveness in acute and chronic schistosomiasis in man.(1978)
- Studies on the adjuvant action of bacterial endotoxins on antibody formation. I. Time limitation of enhancing effect and restoration of antibody formation in x-irradiated rabbits.(1959)
- → The Effects of Antigen Dose and Adjuvant on the Antibody Response; Amplification of Restricted B Cell Clones(1976)19 cited
- Enhancement of Immune Responses to Polysaccharide Antigens Using 8-Mercaptoguanosine.(1984)
- Characteristics of an antigen-adjuvant immunological complex in an experimental vaccineformulation(2020)